Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, Kirsten C., Harasimowicz, Magdalena, Janeczek, Monica, Speiser, Jodi, Swan, James, Tung, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382301/
https://www.ncbi.nlm.nih.gov/pubmed/28424749
http://dx.doi.org/10.1155/2017/9359086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382301/
https://www.ncbi.nlm.nih.gov/pubmed/28424749
http://dx.doi.org/10.1155/2017/9359086

Ejemplares similares